Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Immunologic Research
Erschienen in: Immunologic Research 1-3/2010

01.07.2010

Reconstitution of self-tolerance after hematopoietic stem cell transplantation

verfasst von: Allan D. Hess

Erschienen in: Immunologic Research | Ausgabe 1-3/2010

Einloggen, um Zugang zu erhalten

Abstract

Graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow or hematopoietic stem cell transplantation. GVHD is thought to be primarily due to the response of mature T cells transferred along with the bone marrow graft to foreign histocompatibility antigens expressed on host tissues. Recent studies, however, have challenged this paradigm set forth in the 1960s and have suggested that self-MHC class II antigens can be recognized in GVHD. Many questions still remain unanswered particularly in regard to the role of immune reconstitution, the ability to recognize and discriminate self and the re-establishment of self-tolerance. In fact, the failure to re-establish tolerance to self can lead to systemic autoimmunity that may exacerbate or even mimic GVHD. The present review summarizes our studies in autologous GVHD characterizing the underlying immune mechanisms and their potential impact in allogeneic hematopoietic stem cell transplantation.
Literatur
1.
Kersey JH, Weisdorf D, Nesbit ME, LeBien TW, Woods WG, McGlave PB, et al. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N Engl J Med. 1987;317:461–7.PubMed
2.
Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, et al. Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068–73.PubMed
3.
Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649–53.PubMed
4.
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–62.PubMed
5.
Petersdorf EW. Hematopoietic cell transplantation from unrelated donors. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas’ hematopoietic cell transplantation. Malden: Blackwell; 2004. p. 1132–49.
6.
Shlomchik WD, Coizens MS, Tang CB, et al. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412–5.CrossRefPubMed
7.
Matte CC, Liu J, Anderson BE, et al. Donor APC’s are required for maximal GVHD but not for GVL. Nat Med. 2004;10:987–92.CrossRefPubMed
8.
Reddy PP. Pathophysiology of acute graft-versus-host disease. Hematol Oncol. 2003;21:149–61.CrossRefPubMed
9.
Ferrara LM, Antin J. The pathophysiology of graft-versus-host disease. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas’ hematopoietic cell transplantation. Malden: Blackwell; 2004. p. 353–68.
10.
Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966-67;62:21–35.
11.
Gluckman J, Devergie A, Sohier J, Sauret JH. Graft-versus-host reactions in recipients of syngeneic bone marrow. Lancet. 1980;1:253–6.PubMed
12.
Rappeport J, Reinherz E, Mihm M, et al. Acute graft-versus-host reactions in recipients of bone marrow transplantation from identical twin donors. Lancet. 1979;2:717–20.CrossRefPubMed
13.
Hood AF, Vogelsang GB, Black LP, et al. Acute graft-versus-host disease: development following autologous and syngeneic bone marrow transplantation. Arch Derm. 1987;123:745–51.CrossRefPubMed
14.
Thien SW, Goldman JM, Galton DG. Acute “graft-versus-host disease” after autografting for chronic granulocytic leukemia in transplantation. Ann Intern Med. 1981;94:210–6.
15.
Hess AD, Thoburn CJ. Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-vs-host disease. Immunol Rev. 1997;157:111–23.CrossRefPubMed
16.
Hollander GA, Widmer B, Burakoff SJ. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft-versus-host disease. J Immunol. 1994;152:1609–17.PubMed
17.
Tivol E, Komorowkski R, Drobyski WR. Emergent autoimmunity in graft-versus-host disease. Blood. 2005;105:4885–91.CrossRefPubMed
18.
Teshima T, Reddy P, Liu C, Williams D, Cooke KR, Ferrara JL. Impaired negative selection causes autoimmune graft-versus-host disease. Blood. 2003;102:429–35.CrossRefPubMed
19.
Parkman R. Is chronic graft-versus-host disease an autoimmune disease? Curr Opin Immunol. 1993;5:800–3.CrossRefPubMed
20.
Yamamoto M, Sugihara K, Ohtsuki F, et al. Generation of self HLA-DR specific CD3+ CD4-CD8+ cytotoxic T cells in chronic graft-versus-host disease. Bone Marrow Transpl. 1994;14:525–33.
21.
Jenkins MK, Schwartz RH, Pardoll DM. Effects of CsA on T cell development and clonal deletion. Science. 1988;241:1655–9.CrossRefPubMed
22.
Glazier A, Tutschka PJ, Farmer ER, Santos GW. GVHD in CsA treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med. 1983;158:1–12.CrossRefPubMed
23.
Fischer AC, Beschorner WE, Hess AD. Requirements for the induction and adoptive transfer of syngeneic GVHD. J Exp Med. 1989;169:1031–8.CrossRefPubMed
24.
Jones RJ, Hess AD, Mann RB, et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet. 1989;1:754–7.CrossRefPubMed
25.
Sorokin R, Kimura H, Schroeder K, Wilson DB. Cyclosporine-induced autoimmunity: conditions for expressing disease, requirement for an intact thymus, and potency estimates of autoimmune lymphocytes in drug-treated rats. J Exp Med. 1986;164:1615–26.CrossRefPubMed
26.
Hess AD, Thoburn CJ, Horwitz L. Promiscuous recognition of major histocompatibility complex class II determinants in Cyclosporine-induced syngeneic graft-vs-host disease. Transplantation. 1998;65:785–92.CrossRefPubMed
27.
Chen W, Thoburn C, Hess AD. Characterization of the pathogenic autoreactive T cells in Cyclosporine-induced syngeneic graft-vs-host disease. J Immunol. 1998;161:7040–6.PubMed
28.
Hess AD, Thoburn CJ, Chen W, Bright EC. Unexpected T-cell diversity in syngeneic graft-versus-host disease revealed by interaction with peptide-loaded soluble MHC class II molecules. Transplantation. 2003;75:1361–7.CrossRefPubMed
29.
Hess AD, Bright EC, Thoburn C, et al. Specificity of effector T lymphocytes in autologous graft-vs-host disease: role of the major histocompatibility complex class II invariant chain peptide. Blood. 1997;89:2203–9.PubMed
30.
Thoburn CJ, Miura Y, Bright EC, Hess AD. Functional divergence of antigen-specific T-lymphocyte responses in syngeneic graft-versus-host disease. Biol Blood Marrow Transplant. 2004;10:591–603.CrossRefPubMed
31.
Hess AD, Thoburn CJ, Chen W, Horwitz LR. Complexity of effector mechanisms in syngeneic graft-vs-host disease. Biol Blood Marrow Transplant. 2000;6:13–24.CrossRefPubMed
32.
Sykes M. Mechanisms of tolerance. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas’ hematopoietic cell transplantation. Malden: Blackwell; 2004. p. 300–23.
33.
Hess AD, Fischer AC, Horwitz L, Bright EC, Laulis MK. Characterization of peripheral autoregulatory mechanisms that prevent development of Cyclosporine-induced syngeneic graft-vs-host disease. J Immunol. 1994;153:400–11.PubMed
34.
Taylor PA, Noelle RJ, Blazar BR. CD4+ CD25+ immune regulatory cells are required for induction of tolerance to alloantigen via co-stimulatory blockade. J Exp Med. 2001;193:1311–8.CrossRefPubMed
35.
Tutschka PJ, Hess AD, Beschorner WE, Santos GW. Suppressor cells in the transplantation tolerance. I. Suppressor cells in the mechanism of tolerance in radiation chimeras. Transplantation. 1981;32:203–9.CrossRefPubMed
36.
Tutschka PJ, Hess AD, Beschorner WE, Santos GW. Suppressor cells in transplantation tolerance. III. The role of antigen in the maintenance of transplantation tolerance. Transplantation. 1982;33:510–4.CrossRefPubMed
37.
Tutschka PJ, Ki P, Beschorner WE, et al. Suppressor cells in transplantation tolerance. II. Maturation of suppressor cells in the bone marrow chimera. Transplantation. 1985;32:321–9.CrossRef
38.
Hess AD, Thoburn CJ. Immune tolerance to self-MHC class II antigens after bone marrow transplantation: regulatory role of CD4+ CD25+ Foxp3+ T cells. Biol Blood Marrow Transplant. 2006;12:518–29.CrossRefPubMed
39.
Wu DY, Goldschneider I. Cyclosporin-induced autologous graft-vs-host disease: a prototypical model of autoimmunity and active (dominant) tolerance coordinately expressed induced by recent thymic emigrants. J Immunol. 1999;162:6926–33.PubMed
40.
Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nature Rev. 2003;3:199–210.CrossRef
41.
Hoffmann P, Ermann J, Edinger J, et al. Donor type CD4+ CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:389–99.CrossRefPubMed
42.
Joffre O, Gorssee N, Romagnoli P, et al. Induction of antigen-specific tolerance to bone marrow allografts with CD4+ CD25+ T lymphocytes. Blood. 2004;103:4216–21.CrossRefPubMed
43.
Jiang S, Lechler RI. Regulatory T cells in the control of transplantation tolerance and autoimmunity. Am J Transpl. 2003;3:516–24.CrossRef
44.
Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Ann Rev Immunol. 2004;22:531–62.CrossRef
45.
Jordan MS, Boesteanu A, Reed AJ, et al. Thymic selection of CD4+ CD25+ regulatory T cells induced by an agonistic self-peptide. Nat Immunol. 2001;2:301–6.CrossRefPubMed
46.
Bensinger SJ, Bandeira A, Jordan MS, et al. Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4+ CD25+ immunoregulatory T cells. J Exp Med. 2001;194:427–38.CrossRefPubMed
47.
Watanabe N, Hong-Wang Y, Lee HK, et al. Hassal’s corpuscles instruct dendritic cells to induce CD4+ CD25+ regulatory T cells in human thymus. Nature. 2005;436:1181–5.CrossRefPubMed
48.
Piccirillo CA, Thornton AM. Cornerstone of peripheral tolerance: naturally occurring CD4+ CD25+ regulatory T cells. Trends Immunol. 2004;25:374–80.CrossRefPubMed
49.
50.
Shevach E. Regulatory T cells in autoimmunity. Ann Rev Immunol. 2000;18:423–49.CrossRef
51.
Taylor PA, Panoskaltsis-Mortari A, Swedin JM, et al. L-selectin-hi but not the L-selectin-lo CD4+ 25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood. 2004;104:3804–12.CrossRefPubMed
52.
Fehervari Z, Sakaguchi S. Control of Foxp3+ CD25+ CD4+ regulatory cell activation and function by dendritic cells. Inter Immunol. 2004;16:1769–80.CrossRef
53.
Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–61.CrossRefPubMed
54.
Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+ CD25+ T regulatory cells. Nat Immunol. 2003;4:337–42.CrossRefPubMed
55.
Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family of transcription factor Foxp3. Nat Immunol. 2005;6:331–7.CrossRefPubMed
56.
Miura Y, Thoburn CJ, Bright EC, et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood. 2004;104:2187–93.CrossRefPubMed
57.
Liu JW, Liu ZR, Witkowski P, et al. Rat CD8+ Foxp3+ T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection. Transpl Immunol. 2004;13:239–47.CrossRefPubMed
58.
Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of Foxp3+ CD4+ CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005. Online 21 June 2005.
59.
Rapoport AP, Stadtmauer EA, Aqui N, Vogl D, Chew A, et al. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin Cancer Res. 2009;15:4499–507.CrossRefPubMed
Metadaten
Titel
Reconstitution of self-tolerance after hematopoietic stem cell transplantation
verfasst von
Allan D. Hess
Publikationsdatum
01.07.2010
Verlag
Humana Press Inc
Erschienen in
Immunologic Research / Ausgabe 1-3/2010
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-009-8145-2

Weitere Artikel der Ausgabe 1-3/2010

Immunologic Research 1-3/2010 Zur Ausgabe

OriginalPaper

High-dose cyclophosphamide for autoimmunity and alloimmunity

OriginalPaper

Controlling somatic hypermutation in immunoglobulin variable and switch regions

OriginalPaper

Analysis of gene profile, steady state proliferation and apoptosis of double-negative T cells in the periphery and gut epithelium provides new insights into the biological functions of the Fas pathway

OriginalPaper

Conformational heterogeneity of MHC class II induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection

Erratum

Erratum to: Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence

OriginalPaper

Genetic and biochemical regulation of CD4 T cell effector differentiation: insights from examination of T cell clonal anergy

Neu im Fachgebiet HNO

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Real-World-Daten sprechen eher für Dupilumab als für Op.

14.05.2024 Rhinosinusitis Nachrichten

Zur Behandlung schwerer Formen der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) stehen seit Kurzem verschiedene Behandlungsmethoden zur Verfügung, darunter Biologika, wie Dupilumab, und die endoskopische Sinuschirurgie (ESS). Beim Vergleich der beiden Therapieoptionen war Dupilumab leicht im Vorteil.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise